Oncological diseases

The 159 medicinal products assessed in the field of oncological diseases include products for cell lung carcinoma, multiple myeloma, melanoma and many others. To date, the G-BA has concluded 494 resolutions in this therapeutic area and evaluated a total of 786 patient populations. When these subpopulations are weighted according to their patient share in the resolution, there is a major additional benefit for 1.4% of the populations and a considerable additional benefit for a further 17.9%%. A minor additional benefit has been proved in 14.4% of the subpopulations, with the G-BA identifying a non-quantifiable additional benefit for 17.9% of the subpopulations.

The G-BA has seen no additional benefit proven for 48% of the subpopulations, with 0.5% receiving even less benefit than the comparative therapy. According to the G-BA, a total of 56% of the maximum 1.71 million patients do not see any added value from the assessed medicinal product in relation to an appropriate comparative therapy.